drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease

Clicks: 236
ID: 187596
1998
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Mesalazine is widely used in the treatment of inflammatory bowel disease. Little is known about the doseresponse relationship and about possible dose related side effects. In ulcerative colitis higher dosages of mesalazine (3 g) are more effective in maintaining a remission than lower dosages (1.5 g). In mild to moderately active ulcerative colitis, studies also indicate that higher dosages might be more effective in inducing remission. Dose-comparing studies in Crohn's disease are even more sparse, but the available results indicate higher efficacy at higher dose levels.
Reference Key
mulder1998mediatorsdrug Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;C. J. J. Mulder;S. J. Van Den Hazel
Journal polyhedron
Year 1998
DOI 10.1080/09629359891027
URL
http://dx.doi.org/10.1080/09629359891027
Keywords
safety pathology inflammatory bowel disease side effects drug therapy crohn's disease

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.